title: [A current overview of chemotherapy in advanced gastric cancer].
abstract: Four drugs including 5-fluorouracil (5-FU), adriamycin (ADM), mitomycin C (MMC) and cisplatin (CDDP) can produce response rates ranging from 15% to 20% when used as single agents for advanced gastric cancer. Various combinations employing these agents have been tested and FAM (5-FU, ADM, MMC) has been the most extensively studied, obtaining response rates ranging from 21% to 45% by the original regimen. More recently FAP (5-FU, ADM, CDDP) has been studied and response rates reported were ranged from 29% to 50%, and therefore it was judged that the efficacy is comparable to FAM. However, overall survival gain has been limited when used these combinations. Consequently a serious question has been raised whether past combinations are superior over single agent 5-FU. Prospective randomized trials compared 5-FU alone vs various combination failed to show advantage of combinations over 5-FU alone.
authors.affiliation: Cancer Chemotherapy Center, Japanese Foundation for Cancer Research.
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000970:Antineoplastic Agents; D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil